Radiant Research, a comprehensive clinical research company that provides Phase I-IV clinical drug development and conduct services to the biopharmaceutical industry, has developed significant and growing expertise in vaccine development.
The company’s focus on standard operational processes to align its many research centers gives vaccine developers the ability to rapidly initiate and execute vaccine studies.
By leveraging its centralized database of study participants and marketing support, Radiant Research can identify large numbers of study volunteers, deploy staff for large enrollments and execute vaccine trials with speed and precision.
For example, in a yellow fever vaccine trial, Radiant’s research firm enrolled 80 subjects in eight weeks. In a flu study, one center recruited 115 participants in four weeks. In addition to a rapid, smooth start for studies, the company’s one point of contact and one source contracting process can save weeks, or months, in large multi-center studies.
The trial sponsor’s dedicated Radiant clinical conduct manager helps evaluate Radiant assets at the feasibility stage. This provides a base of information on the sponsor’s needs, which expedites selection of centers for the study. Rather than looking at many individual centers, the Radiant method saves the sponsor time by bringing forward multiple centers that match the sponsor’s needs for facilities, expertise, staff and local participant databases.
The company’s standard processes include other service features that enable trials to move smoothly from beginning to end:
Local promotion of trial recruitment combined with centralized strategic marketing capabilities enhances recruitment.Standard operations, quality training and independent quality assurance processes help ensure data consistency within and across centers;
Dedicated regulatory managers at each center provide the necessary focus to ensure 72-hour turnaround of regulatory documents;Use of a central IRB speeds approvals Large rooms for block enrollment and high-volume participant management are available nationwide.
The company has executed over 200 vaccine trials, ranging from pilot studies, tolerability and immunogenicity, to comparative studies on dose ranging, lot consistency and age.
As an enterprise, the company has more than 400 experienced professionals placed in 25 wholly-owned research centers. They have completed more than 8,000 trials from Phase I-IV and can access databases of more than one million potential study participants.
